Signal2026-06-17
ClinicalTrials.gov

[PHASE2] Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.

Part of

Molecular Profiling In Endocrine Neoplasms

Open primary sourceSee the whole picture